IN8bio, Inc. develops gamma-delta (γδ) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases. Company news centers on clinical and preclinical pipeline updates, including DeltEx Drug-Resistant Immunotherapy γδ T cells in newly diagnosed glioblastoma, INB-100 allogeneic γδ T cells for high-risk leukemias after haploidentical stem cell transplantation, and γδ T cell engager work for oncology and autoimmune indications.
Recurring updates also cover financial results, clinical data presentations at medical meetings, R&D communications, financing activity, Nasdaq inducement grants, and leadership or board changes. The company operates as a clinical-stage biopharmaceutical issuer with common stock traded on Nasdaq under INAB.
IN8bio (Nasdaq: INAB)/b) reported Q1 2026 results and program updates on May 7, 2026. Key clinical highlights include a reported for repeat-dose GBM patients versus 6.6 months for SOC (+97%) and mOS of 17.2+ months. Cash was $21.9M as of March 31, 2026.
The company advanced its INB-619 γδ T cell engager into IND-enabling studies with initial animal data expected in 2026 and will present updated mOS data at ASCO 2026.
IN8bio (Nasdaq: INAB) announced presentations and new clinical data on its γδ T cell programs at multiple May–June 2026 conferences, and an R&D Day on May 21, 2026. Key items include a Phase I INB-200 GBM poster at ASCO June 1, 2026, an ASGCT oral presentation, ISCT posters, and R&D Day details.
Materials will be posted on the company's investor website after each meeting.
IN8bio (Nasdaq: INAB) granted inducement stock options to two new employees to purchase an aggregate of 11,800 shares, with a grant date of April 1, 2026 under Nasdaq Listing Rule 5635(c)(4).
The nonqualified options vest over four years (25% after one year, then 36 equal monthly installments), were approved by the Compensation Committee, and were issued outside the company’s 2023 Equity Incentive Plan as an inducement to employment.
IN8bio (Nasdaq: INAB) reported Q4 and full-year 2025 results, updated GBM clinical data, pipeline progress, leadership promotion, and a strengthened balance sheet.
Repeat-dose DeltEx DRI patients showed mPFS of 13.0 months vs. 6.6 months for SOC (+97%). Cash was $27.1M at year-end; initial private placement tranche raised $20.1M (up to $40.2M) with net proceeds of $18.5M, extending runway into H1 2027.
IN8bio (Nasdaq: INAB) announced that CEO and co-founder William Ho will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:50 am ET in Boston. The company will host one-on-one investor meetings March 2-4.
A live webcast and replay will be available via the company’s Events and Presentations page at https://investors.in8bio.com.
IN8bio (Nasdaq: INAB) promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective February 9, 2026. Dr. Rochlin has served as COO since December 2021 and held prior operations roles since August 2020.
She brings over 17 years of biotech experience and will continue to oversee operations, manufacturing, clinical programs and advancement of the company’s γδ T cell therapies and T cell engager pipeline, including INB-619 preclinical progress showing complete B cell depletion with limited cytokine release.
IN8bio (Nasdaq: INAB) announced CEO and co-founder William Ho will present at two February investor and scientific conferences: Noble Emerging Growth Virtual Equity Conference on Feb 5, 2026 (3:00 p.m. ET, virtual) and IO360° Conference on Feb 12, 2026 (1:20–1:40 p.m. ET) with a plenary on DeltEx DRI and Phase 1/2 GBM results.
Webcast and registration details will be posted in the company’s Events & Presentations section at the corporate website.
IN8bio (NASDAQ: INAB) reported updated Phase 1/2 data for repeat-dose DeltEx™ Drug-Resistant Immunotherapy γδ T cells (DeltEx DRI) in newly diagnosed glioblastoma presented Jan 12, 2026. Across multiple centers (DeltEx DRI N=14; contemporaneous SOC N=10) median progression-free survival mPFS was 13.0 months vs 6.6 months for SOC (+97%). Median overall survival mOS is currently 17.2+ months for DeltEx DRI versus 13.2 months for SOC (+30.3%), with several patients progression-free 1.4–4.6 years. Treatment was well tolerated: no DLTs, no treatment-related SAEs, no CRS, and no ICANS. Company will use late‑2025 financing to support FDA discussions on potential clinical pathways.
IN8bio (Nasdaq: INAB) announced a private placement priced at-the-market to raise up to $40.2 million, with an initial closing of approximately $20.1 million expected around Dec 22, 2025. The initial tranche sells 5,127,029 shares at $1.38 and pre-funded warrants for up to 9,452,677 shares (exercise price $0.0001). The company may receive an additional $20.1 million subject to preclinical milestones and share-price conditions. Net proceeds are intended to fund IND-enabling studies for INB-619, generate early animal data in 2026, support potential IND submission in 2027, submit INB-200/INB-400 glioblastoma data to the FDA, and provide working capital into the first half of 2027.
IN8bio (Nasdaq: INAB) reported Q3 2025 results and program updates on Nov 6, 2025. The company presented new preclinical data on INB-619 showing CD19-targeted γδ T cell engager potency comparable to FDA-approved CD19/CD20 engagers with minimal cytokine release, and advanced its γδ T cell platform.
IN8bio expanded the Phase 1 INB-100 trial to The Ohio State University to accelerate enrollment and plans updated INB-200/400 GBM data at SNO (Nov 19-23, 2025) and additional INB-619 preclinical data at ASH (Dec 6-9, 2025).
Q3 financials: R&D $2.1M, G&A $1.9M, net loss $3.9M (‑$0.85/share), and cash $10.7M as of Sep 30, 2025.